Wave life sciences announces topline data and addition of higher dose cohort in ongoing phase 1b/2a precision-hd2 trial in huntington’s disease

Wave life sciences announces topline data and addition of higher dose cohort in ongoing phase 1b/2a precision-hd2 trial in huntington’s disease.wave life sciences ltd - wve-120102 demonstrates statistically significant reduction in disease-causing mutant htt protein in csf versus. placebo.wave life sciences ltd - no difference in total htt protein or neurofilament light chain in treated patients versus. placebo.wave life sciences ltd - additional cohort for wve-120102 expected to initiate in january 2020.wave life sciences ltd - wve-120102 was generally safe and well tolerated across all cohorts.wave life sciences ltd - data support addition of higher dose cohorts, co expects to initiate a 32 mg cohort in jan. 2020.wave - there was no difference in thtt versus. placebo; wve-120102 may have potentially differential effect on huntingtin measured by mhtt, thtt assays.wave life sciences - there were no serious adverse events related to treatment with wve-120102 and no study stopping rules were met.wave life sciences - topline results from precision-hd1, including those from 32 mg cohort, are now expected in h2 2020.wave life sciences ltd - will continue to explore potential effects of wve-120102 on huntingtin as measured by mhtt & thtt assays, with higher doses.
WVE Ratings Summary
WVE Quant Ranking